ACE Report Cover
AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect.
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
SPORTS MEDICINE
AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect. .

Costal ChondrocyteDerived PelletType Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect: a Randomized Phase 3 Clinical Trial Compared to Microfracture

Contributing Authors

J Lee KH Yoon JY Park Seungwook Moon

One hundred four patients with ICRS grade 3 or 4 articular cartilage defects of the knee (2–10 cm² in area, ≤4 cm³ in volume) were randomized to receive CCP-ACI (n=52) or MFx (n=52). The primary outcome of interest was the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score. Secondary outcomes of interest included complete defect repair, tissue integration, signal intensity of repair tissue, and clinical outcomes. Outcomes were assessed at 8, 24, and 48 weeks. Overall, the results of the study revealed significantly greater MOCART scores and structural cartilage repair in the CCP-ACI group at 24 and 48 weeks, although clinical improvements were comparable between groups. These findings suggest that CCP-ACI leads to better structural regeneration than MFx, with similar clinical benefits in the short term.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect.. ACE Report. 2025;307(3):96. Available from: https://myorthoevidence.com/AceReport/Show/aaos-2025-costal-chondrocyte-pellet-aci-vs-microfracture-for-articular-cartilage-defect

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report